- Home
- YDES vs ZURA Comparison
YDES vs ZURA Comparison
Compare YDES & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YDES | ZURA |
|---|---|---|
| Founded | 2013 | 2022 |
| Country | Taiwan | United States |
| Employees | N/A | 40 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.0M | 455.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | YDES | ZURA |
|---|---|---|
| Price | $3.37 | $3.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 11.6K | ★ 856.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.88 | $1.00 |
| 52 Week High | $25.00 | $7.25 |
Technical Indicators
Market Signals| Indicator | YDES | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 37.96 |
| Support Level | $2.88 | $3.25 |
| Resistance Level | $5.36 | $4.12 |
| Average True Range (ATR) | 0.43 | 0.25 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 20.88 | 39.50 |
Price Performance
Historical ComparisonAbout YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.